Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Arch Therapeutics Inc ARTH

Consumer Cyclical Healthcare Medical Instruments & Supplies
Arch Therapeutics, Inc. is a biotechnology company developing and marketing products based on its AC5 self-assembling technology platform. These products can be advances in the field of stasis and barrier applications. The Company’s flagship products and product candidates are derived from its AC5 self-assembling peptide (SAP) technology platform and referred to as AC5 or the AC5 Devices. These... see more

Recent & Breaking News (OTCQB:ARTH)

Arch Therapeutics Obtains Additional Safety Data for Its AC5 Surgical Hemostatic Device(TM) in Successful Preclinical Toxicity Test

Marketwired June 9, 2015

Arch Therapeutics Initiates Research and Development Collaboration With CURAM Centre for Research in Medical Devices

Marketwired June 1, 2015

Arch Therapeutics to Present at 2015 LD MICRO Invitational Conference on June 1

Marketwired May 18, 2015

Arch Therapeutics' AC5(TM) Compared Favorably vs. Commercially Available Combination Hemostat in Animal Study

Marketwired April 16, 2015

Presentation Schedule Now Available for RedChip's April 22-23 Global Online CEO Conference

GlobeNewswire April 15, 2015

Arch Therapeutics Announces Favorable Preclinical Data From an Independent Study of AC5 Surgical Hemostatic Device(TM) Versus a Popular Fibrin Sealant

Marketwired April 14, 2015

Arch Therapeutics Announces Favorable Preclinical Data from an Independent Study of AC5 Surgical Hemostatic Device(TM) Versus a Popular Cellulose-Based Hemostatic Agent

Marketwired March 25, 2015

Arch Therapeutics Announces Positive Safety Results for AC5 Surgical Hemostatic Device(TM) in Preclinical Toxicity Studies

Marketwired March 23, 2015

RedChip TV Announces Lineup for This Week's Show on Bloomberg, DIRECTV, and Dish Network

GlobeNewswire March 6, 2015

RedChip TV Announces Lineup for This Week's Show on Bloomberg, DIRECTV, and Dish Network

GlobeNewswire February 27, 2015

Pre-Clinical Animal Pilot Study Shows Arch Therapeutics' AC5(TM) Compared Favorably Versus a Popular Hemostatic Agent

Marketwired February 23, 2015

Nanomedicine: Nanotechnology, Biology, and Medicine Publishes Preclinical Data on Arch Therapeutics' AC5 Surgical Hemostatic Device(TM)

Marketwired February 19, 2015

The British Standards Institution Classifies Arch Therapeutics' AC5(TM) as a Medical Device Within the European Union

Marketwired February 17, 2015

Arch Therapeutics Obtains Additional Positive Results for AC5 Surgical Hemostatic Device(TM) in Preclinical Safety Study

Marketwired January 13, 2015

Arch Therapeutics Announces Positive Results for AC5 Surgical Hemostatic Device(TM) in Biochemical and Cell Function Safety Studies

Marketwired January 6, 2015

Arch Therapeutics to Present at The Biotech Showcase(TM) 2015 Conference on January 14th 2015

Marketwired December 17, 2014

Arch Therapeutics to Present at LD Micro Main Event on December 4th 2014

Marketwired November 24, 2014

Arch Therapeutics Reports Positive Preclinical Data from Study of AC5 Surgical Hemostatic Device(TM) in Animals Treated with Brilinta(R) (ticagrelor)

Marketwired November 18, 2014

Arch Therapeutics Will Present at Two Investor Conferences in November

Marketwired November 10, 2014

Arch Therapeutics Reports Positive Preclinical Data From Study of AC5 Surgical Hemostatic Device(TM) in Animals Treated With the Antiplatelet Medications Plavix(R) (Clopidogrel) and Aspirin

Marketwired November 6, 2014